Recoclix targets patients who suffer from undefined intestinal pain, which is often associated with pathology such as Irritable Bowel Syndrome (IBS). The prevalence of IBS varies widely, and much remains undiagnosed, but in the United States it is estimated that over 14% of the population is affected, with an annual cost to the economy of over $20 billion.